Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
Articolo
Data di Pubblicazione:
2022
Citazione:
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial / Tam, C.S., Brown, J.R., Kahl, B.S., Ghia, P., Giannopoulos, K., Jurczak, W., Šimkovič, M., Shadman, M., Österborg, A., Laurenti, L., Walker, P., Opat, S., Chan, H., Ciepluch, H., Greil, R., Tani, M., Trněný, M., Brander, D.M., Flinn, I.W., Grosicki, S., et al.. - In: THE LANCET ONCOLOGY. - ISSN 1474-5488. - 23:8(2022), pp. 1031-1043. [10.1016/S1470-2045(22)00293-5]
Abstract:
Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). We compared zanubrutinib with bendamustine-rituximab to determine its effectiveness as frontline therapy in patients with CLL or SLL.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Piperidines; Pyrazoles; Pyrimidines; Rituximab; COVID-19; Leukemia, Lymphocytic, Chronic, B-Cell; Sequoia
Elenco autori:
Tam, Constantine S; Brown, Jennifer R; Kahl, Brad S; Ghia, Paolo; Giannopoulos, Krzysztof; Jurczak, Wojciech; Šimkovič, Martin; Shadman, Mazyar; Österborg, Anders; Laurenti, Luca; Walker, Patricia; Opat, Stephen; Chan, Henry; Ciepluch, Hanna; Greil, Richard; Tani, Monica; Trněný, Marek; Brander, Danielle M; Flinn, Ian W; Grosicki, Sebastian; Verner, Emma; Tedeschi, Alessandra; Li, Jianyong; Tian, Tian; Zhou, Lei; Marimpietri, Carol; Paik, Jason C; Cohen, Aileen; Huang, Jane; Robak, Tadeusz; Hillmen, Peter
Link alla scheda completa:
Pubblicato in: